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Purpose: To report the clinical features and investigate the underlying pathological processes of spontaneous corneal
perforation in patients with ocular chronic graft-versus-host disease (cGVHD).
Methods: A full ophthalmological evaluation of corneal perforation in four patients with cGVHD was performed. Three
of  them  underwent  deep  anterior  lamellar  keratoplasty  and  samples  from  two  of  three  patients  were  used  for
histopathological analyses.
Results: Three patients were successfully treated by corneal transplantation. One patient was treated with a therapeutic
soft contact lens, and the wound healed within 2 days. The common clinical features of these patients were (1) the presence
of definite dry eye related to cGVHD in 3 of 4 patients and probable dry eye in one patient, (2) a central or paracentral
site of corneal ulceration and perforation, with no sign of infection, and (3) prior use of a topical or systemic corticosteroid,
and/or topical non-steroidal anti-inflammatory drugs. Immunohistochemical findings revealed an increased number of
cluster of differentiation 68+ (CD68+) macrophages and matrix metalloproteinase 9 (MMP-9) expression in the tissue
surrounding the perforation.
Conclusions: Our report extends current information on the clinical features and pathological processes of corneal
perforation in cGVHD by showing increased MMP-9 expression and the accumulation of CD68+ positive macrophages
in the affected areas.
Allogenic  hematopoietic  stem  cell  transplantation
(HSCT) is now a curative therapy for several hematological
malignancies  and  inherited  disorders  [1].  As  a  result,  the
number of HSCTs performed annually (about 25,000) has
increased worldwide, as has the incidence of chronic graft-
versus-host  disease  (cGVHD),  a  serious  complication
following HSCT [2]. The eye is a frequent target of cGVHD
after HSCT, with the involvement of both the ocular surface
and posterior ocular structures [3,4]. In particular, the effects
of  cGVHD  on  the  cornea  can  cause  irreversible  damage,
including  corneal  calcification,  ulceration,  thinning,  and
melting [5-7]. In patients with cGVHD after HSCT, corneal
perforation is a serious condition that can lead to blindness.
Several etiologies for corneal perforation in cGVHD have
been proposed, including the presence of apoptotic cells, and
immunological reactions in perforated cornea [8-11].
Here, we studied 4 cases of corneal perforation associated
with cGVHD and described the patients’ clinical histories,
analyzing common factors that could contribute to corneal
perforation.  We  also  described  histopathological  and
immunohistochemical  findings  from  cGVHD  perforated
corneal samples.
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METHODS
Four eyes of 4 patients with ocular cGVHD (1 female, 3 males;
median age, 59 years (range 21 to 70) and corneal perforation
were studied. The type of HSCT was allogenic peripheral
blood  stem  cell  transplantation  (PBSCT)  in  2  cases  and
allogeneic  bone  marrow  transplantation  with  a  reduced-
intensity preparative regimen in 2 cases. The diagnosis of
corneal perforation was made by slit-lamp examination in
combination with a Seidel’s test. We diagnosed dry eye when
tear film instability was detectable (Tear break up time ≤5 s
and/or Schirmer test ≤5 mm) and any abnormality of ocular
surface (Rose Bengal score ≥3 and/or fluorescein staining
score ≥3) and symptoms of ocular irritation. Definite dry eye
was defined as having all three components including tear film
instability, abnormality of ocular surface and, symptoms of
ocular irritation. Probable dry eye was defined as having one
of either tear film instability or abnormality of ocular surface
along  with  symptom  of  ocular  irritation  [12].  Meibomian
gland dysfunction (MGD) was scored by Shimazaki’s grading
system [13]. The assessment of obstruction of the meibomian
gland orfice was conducted by digital pressure applied on the
upper tarsus, and the degree of ease in expressing meibomian
secretion  (meibum)  was  evaluated  semi-quantitatively  as
follows; grade 0, clear meibum is easily expressed; grade 1,
clear meibum is expressed with more than moderate pressure;
grade 2, cloudy meibum is expressed with more than moderate
pressure; and grade 3, meibum cannot be expressed even with
the hard pressure.
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598All four patients fulfilled the National Institutes of Health
(NIH, Bethesda, MD) consensus criteria for a diagnosis of
cGVHD [14], which was at least 1 diagnostic clinical sign of
cGVHD or the presence of at least 1 distinctive cGVHD
manifestation (e.g., keratoconjunctivitis sicca) confirmed by
pertinent biopsy or other relevant tests (e.g., Schirmer test) in
the same or another organ. The time from HSCT to corneal
perforation,  from  the  onset  of  corneal  ulcer  to  corneal
perforation, and from HSCT to the onset of dry eye were
determined. We also analyzed the position and size of the
corneal ulcers and corneal perforation and the degree of dry
eye.  We  examined  samples  of  perforated  corneal  tissue
obtained during keratoplasty. We could not obtain a sample
of perforated corneal tissue from one of the three patients
during surgery. Therefore, we performed histological studies
on samples from only two patients. Eye bank corneas from
overseas were used as controls.
Our  research  protocols  followed  the  tenets  of  the
Declaration of Helsinki, and informed consent was obtained
from all the subjects after an explanation of the nature and
possible consequences of the study. We obtained approval for
this study from the IRB/Ethics committee at Keio University.
A portion of each corneal specimen was immediately
embedded  in  Tissue-Tek  O.C.T.  compound  (Miles  Inc.,
Elkhart,  IN)  and  stored  at  –80  °C  until  sectioning.  The
remainder of each sample was fixed in 10% neutral buffered
formalin, embedded in paraffin wax, processed according to
conventional  histologic  techniques,  and  stained  with
hematoxylin-eosin. Frozen sections 5-μm thick were used for
immunohistochemical  analyses,  which  were  performed
according to a standard protocol [15,16]. Briefly, the sections
TABLE 1. CLINICAL CHARACTERISTICS OF CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS WITH CORNEAL PERFORATION.
Case number Case 1 Case 2 Case 3 Case 4
Age (Years), sex 62, M 21, M 70, M 56, F
Underlying disease AML (M4) AML (M0) AML (M4) CML
Type of treatment Allo-PBSCT mini BMT Allo-PBSCT mini BMT
Onset of dry eye (month) 6 4 4 N.A.
Onset of corneal perforation (month) 17 20 30 8
Schirmer Test (mm) 1 0 4 10
Fluorescein Score (9 points) 9 9 3 3
MGD score (3 points) Unknown 3 3 Unknown
External bacterial flora culture MRSA Trichosporon spp. MRSA negative
Entropion − + + −
Corneal neovascularization − + + −
Topical drops (corticosteroid) + (1 day)* + (5 years)** + (3 weeks)*** −
Topical drops (NSAIDS) − − + (3 weeks)§ + (4 months)¶
Oral corticosteroids (PSL) + (3 months) + (15 mg) (6 months) + (10 mg) (> 2 years) + (> 20 mg) (2 months)
        AML,  acute  myeloid  leukemia;  CML,  chronic  myeloid  leukemia;  allo-PBSCT,  allogeneic  peripheral  blood  stem  cell
        transplantation; MGD, meibomian gland dysfunction; MRSA, methicillin-resistant Staphylococcus aureus; mini BMT, mini
        bone marrow transplantation, reduced intensity of conditioning regimen for hematopoietic stem cell transplantation; NSAIDS,
        non-steroidal  anti-inflammatory  drugs;  *,  dexamethasone  sodium  phosphate;  **,  0.02%  fluorometholone;  ***,  0.1%
        fluorometholone; §, dicrofenac sodium;¶, bromfenac sodium, Topical corticosteroids were used 4 times per day; Topical
        NSAIDS were used 2 times per day. The dose (per day) and duration of oral corticosteroid were shown in the table. PSL,
        predonisolone; mo, months.
TABLE 2. CLINICAL FINDINGS OF CORNEAL ULCER AND PERFORATION.
Case number Case 1 Case 2 Case 3 Case 4
Size of corneal ulcer (mm) 2.0×1.5 2.0×2.5 2.0×1.5 3.5×1.5
Position of corneal ulcer center paracenter paracenter paracenter
Size of corneal perforation (mm) 0.5×0.5 0.5×1.0 0.5×0.5 2.0×1.0
Position of corneal perforation center paracenter paracenter paracenter
Period from corneal ulcer to perforation (day) 7 12 within 35 within 27
Preoperative visual acuity 20/100 LP (+) 20/250 20/250
Surgical intervention glue, DALK DALK MUCL DALK
Postoperative visual acuity 20/200 20/250 20/50 20/500
Observation periods (month) 7 2 40 15
          MUCL, medical use contact lens ; DALK, deep anterior lamellar keratoplasty.
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599were blocked with 10% goat serum for 1 h and then were
incubated a panel of mouse monoclonal antibodies against
cluster of differntiation 4+ (CD4; RPA-T4; Biolegend, San
Diego,  CA),  cluster  of  differentiation  8+  (CD8;  C8/144B;
Nichirei  Bioscience,  Tokyo,  Japan),  and  cluster  of
differentiation 68+ (CD68+; Dako, Glostrup, Denmark), and a
peroxidase-conjugated  rabbit  anti-mouse  secondary  IgG
(Dako).  Matrix  Metalloproteinase-2  (MMP2)  was  labeled
with  a  rabbit  anti-human  MMP2  antibody  (Daiichi  Fine
Chemical Co., LTD., Toyama, Japan), and MMP9 with a
Figure 1. Clinical findings of perforated cornea before and after treatment with deep anterior lamellar keratoplasty or glue. A, B: Case 1
photographs of the perforated cornea upon admission (left eye). A: The perforation was located in the paracentral cornea. The size of the
perforation was 0.5 mm×0.5 mm. The surrounding ulcer was 2.0 mm×1.5 mm. B: Preoperative photo showing a positive Seidel test. C:
Photograph of the cornea after deep anterior lamellar keratoplasty. Five months later, the corneal graft remained stable and transparent. D,
E: Case 2 slit lamp photograph taken upon admission (right eye). D: The perforation was in the paracentral cornea and was 0.5 mm×1.0 mm.
E: Photograph showing the paracentral corneal perforation plugged by the iris. F: Slit lamp photograph after the operation. One year after
deep anterior lamellar keratoplasty, the corneal graft was stable and transparent. G, H: Case 3 slit lamp photograph taken upon admission (left
eye). G: The perforation was inferior to the center of the cornea and was 0.5 mm×0.5 mm. An ulcer (2.0 mm×1.0 mm) was observed inferiorly.
H: The anterior chamber was maintained by the prolapsed iris. I: Slit lamp photograph 3 months after healing of the perforated cornea without
surgical intervention. J: Case 4 slit lamp photograph taken upon admission (right eye). The perforation was located inferior to the center of
the cornea. The cornea was 3.5 mm×1.5 mm, and the perforation was 2.0 mm×1.0 mm. The Seidel test was positive.
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600mouse  anti-human  MMP9  antibody  (Dako)  [15,16].  The
secondary antibodes for MMP2 and MMP9 were Alexa 488-
conjugated goat anti-mouse (Molecular Probes, Eugene, OR).
Nuclei  were  counterstained  with  TO-PRO-3  (Molecular
Probes).  Isotype-matched  fluorescein-conjugated  mouse
antibodies were used as controls. The sections were examined
with an ECLIPSE E800 microscope (Nikon, Tokyo, Japan) or
a  LSM5  PASCAL  510  confocal  microscope  (Carl-Zeiss,
Göttingen, Germany).
RESULTS
Clinical  manifestations  in  4  cases  of  corneal  perforation
associated with cGVHD: The clinical characteristics of the 4
patients with cGVHD are shown in Table 1 and Table 2. Three
of 4 patients had definite dry eye, and one patient had probable
dry eye, before the onset of corneal ulcer and perforation. The
mean onset of dry eye related to cGVHD in 3 of 4 patients was
4.7±1.2  months  after  HSCT,  which  is  typical  for  this
condition.  Severe  obstruction  of  meibomian  gland  orfice
(grade  3),  entropion,  and  corneal  neovascularization  were
observed in 2 of the 4 cases. The mean onset of corneal
perforation  after  HSCT  for  all  four  cases  was  23.8±8.1
months.  The  time  from  the  diagnosis  of  corneal  ulcer  to
perforation was 1 to 5 weeks. The mean time from the onset
of dry eye to corneal perforation was 17.7±7.6 months. The
corneal perforations were all central or paracentral (Table 2),
and there was no indication of infection in any of the cases.
Conjunctival  hyperemia  and  corneal  opacity  were  not
prominent in these samples of cGVHD-associated corneal
perforation, although these findings are frequent in cases of
Sjögren’s syndrome and infection. The size of perforations
was  relatively  small,  ranging  from  0.5×1.0  mm  to
0.5×2.0 mm. Three patients were treated with deep anterior
lamellar keratoplasty (DALK). The fourth patient was treated
successfully by using therapeutic soft contact lenses, and no
surgery was required (Table 2). Following treatment, all the
patients showed a stable ocular surface condition.
Case 1—A 62-year-old man had been treated for acute
myelogenous  leukemia  (AML;  M4)  with  an  allogeneic
peripheral  blood  stem  cell  transplant  from  an  human
leukocyte antigen (HLA)-matched sibling in April, 2006. Six
months later, he presented with severe dry eye related to
cGVHD. The dry eye was treated at a local eye clinic with
commercially available tear substitutes and punctal plug. In
August,  2007,  the  subject  exhibited  a  grouped  vesicular
eruption over dermatome V1 on his right forehead. Five days
later, he developed superficial punctate keratitis, and uveitis
in the right eye, and corneal erosion in the left eye. He was
treated with topical eye medications that contained acyclovir
(Santen  Pharmaceutical  Co.  Ltd.,  Osaka,  Japan),  sodium
hyaluronate, (Santen Pharmaceurical Co. Ltd, Osaka, Japan)
and betamethasone sodium phosphate (Shionogi & Co., Ltd.,
Osaka, Japan) for both eyes and gatifloxacin hydrate (Senju
Pharmaceutical  Co.,  Ltd.,  Osaka,  Japan)  and  1%  atropine
sulfate (Nitten Pharmaceutical Co., Ltd., Nagoya, Japan) for
the right eye. However, after 1 day of this treatment, the
patient developed a central corneal perforation of the left eye
(Figure 1A,B). Cyanoacrylate glue therapy was attempted, but
failed on the following day. The perforation was then treated
by DALK. Best-corrected visual acuity (BCVA) at the 6-
month follow up was 20/200. The corneal graft attached well
and was stable (Figure 1C).
Figure 2. Pathological findings. A, B:
Case  4  frozen  tissue  section  (cornea,
hematoxylin & eosin staining, original
magnification 40×, 100×). B: Magnified
view of boxed area with an arrow in A.
Corneal tissue near the perforation. C,
D:  Frozen  tissue  section  (cornea,
hematoxylin & eosin staining, original
magnification  100×,  200×)  Corneal
tissue  near  the  perforation.  The
epithelium  neighboring  the  corneal
ulcer showed partial thinning (arrow).
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601Case 2—A 20-year-old man had been treated for AML
(M0)  with  allogeneic  peripheral  blood  stem  cell
transplantation (PBSCT) in March, 2005. Two months later,
severe cGVHD-related dry eye was diagnosed and treated
with  tear  substitutes,  including  eyedrops  containing
autologous sera and 0.1% topical sodium hyaluronate, 0.02%
fluorometholone  (Santen  Pharmaceurical  Co.  Ltd.)  and
levofloxacin (Santen Pharmaceurical Co. Ltd.). Eight months
after the diagnosis of severe dry eye, he was referred to our
hospital  with  epiphora  from  his  left  eye,  and  slit  lamp
examination revealed a perforation in the center of the cornea
(Figure 1D,E). BCVA on his first visit was light perception in
the left eye. He underwent DALK. BCVA at the 2-year follow
up was 20/200. The graft remained clear and no recurrence
was observed (Figure 1F).
Case 3—A 70-year-old man had been treated for AML
(M4) with allogeneic PBSCT in April, 2002. Two years later,
he experienced mild dry eye with superficial punctate keratitis
in  both  eyes.  Four  months  after  the  onset  of  dry  eye,  he
underwent cataract surgery of both eyes, and his post-surgical
treatment  included  topical  non-steroidal  anti-inflammatory
eye drops (topical 0.1% diclofenac sodium; Wakamoto Co.,
Ltd, Tokyo, Japan) and topical 0.1% fluorometholone. Three
weeks  after  the  cataract  surgery,  corneal  perforation  was
diagnosed at a local clinic, and the patient was referred to our
hospital. The perforation was inferior to the center of the
cornea on the left eye (Figure 1G). An ulcer was observed
inferior  to  the  perforation.  The  anterior  chamber  was
maintained by the incarcerated prolapsed iris (Figure 1H).
BCVA upon presentation was 20/200 in the left eye. He was
treated with a therapeutic contact lens, and the wound had
healed by the second day after admission. On the 5th day, re-
epithelization was evident. Three months later, a slit lamp
examination showed that the perforated cornea had healed
without surgical intervention (Figure 1I). BCVA at the 3-year
follow up was 20/50.
Case 4—A 56-year-old female patient had been treated
for  AML  with  allogenic  PBSCT  from  an  HLA-identical
sibling after a reduced-intensity preparative regimen, in July,
2002. Five months later, she had dry eye sensation and painful
eye with full areas of punctate keratopathy and liver cGVHD.
Probable dry eye related to cGVHD was present and treated
with  tear  substitutes  and  topical  nonsteroidal  anti-
inflammatory  eye  drops  (bromfenac  sodium  hydrate  eye
drops; Senju Pharmaceutical co, Ltd, Osaka, Japan). Sytemic
cGVHD was treated with an oral predonisolone. Nine months
after  HSCT,  she  presented  with  epiphora,  a  paracentral
corneal perforation of her right eye was diagnosed (Figure 1J),
and she was referred to our hospital for treatment. BCVA upon
presentation  was  20/200  in  the  right  eye.  An  ulcer  was
observed inferior to the perforation. The perforated cornea
was treated with DALK. A slit lamp examination 5 months
after the surgery showed a clear and stable corneal graft.
BCVA at the 1-year follow up was 20/200.
Histopathologic findings: To investigate the histopathology
of cGVHD-associated corneal perforation, we used samples
from  case  patients  1  and  4,  obtained  during  DALK.
Hematoxylin and eosin staining of both perforated corneal
Figure 3. Immunohistochemical findings (CD4, CD8, and CD68). A: CD68 expression at the margin of the corneal ulcer from case 4 sample.
B, C: CD8+ (B) and CD4+ (C) T cells were not detected in this sample. E, F: Control samples for CD8 (E) and CD4 (F) immunostaining.
D: Control sample. CD68 immunostaining.
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602samples revealed almost no neutrophilic infiltration in the
stroma near the corneal ulcer. Melting of the corneal stroma
was observed locally; however, the rest of the stromal tissue
remained intact. The epithelium neighboring the corneal ulcer
showed partial thinning (Figure 2A,B; patient 4) compared
with normal control corneal tissue (data not shown). Similar
findings were observe in the perforated cornea obtained from
another patient. (Figure 2C,D; patient 1).
Immunohistochemistry: Staining for CD68 showed intense
expression on mononuclear cells around the margin of the
corneal ulcer in the sample from case 1 (Figure 3A), but
scarcely detected in the control samples (Figure 3D). Both
CD8+ (Figure 3B,E) and CD4+ (Figure 3C,F) T cells were not
detected in these samples or control samles. Immunostaining
for  MMP9,  also  known  as  type  IV  collagenase,  showed
intense expression in the stroma (Figure 4A,B) and epithelium
(Figure  4B)  of  the  perforated  cornea  from  a  patient  with
cGVHD.  However,  no  immunoreactivity  for  MMP2  was
detected (Figure 4C). MMP9 was not detected in the negative
control samples (Figure 4F).
DISCUSSION
In  this  study,  we  individually  described  the  clinical
characteristics of four patients with corneal perforation. As
common factors in our cases of cGVHD-associated perforated
cornea, we noted definite dry eye related to cGVHD in 3 of 4
patients and one patient had new onset of probable dry eye
related  to  cGVHD  and  the  use  of  topical  or  systemic
corticosteroids  and/or  topical  NSAIDS  before  the  corneal
perforation. In addition, in all of the cases, the corneal ulcer
and perforation occurred centrally or paracentrally with no
sign  of  infection  or  neutrophilic  infiltration.  We  also
performed histologic and immunohistologic examinations of
perforated cornea tissue samples from two patients. To our
knowledge,  we  have  shown  for  the  first  time  MMP9
expression  and  CD68+  macrophages  accumulation  in  the
tissue surounding the perforation which may contribute to
corneal perforation in patients with cGVHD.
Dry  eye  associated  with  cGVHD  is  a  major  late
complication after HSCT [3,4,17]. The new onset of dry eye,
gritty  and  painful  eyes,  and  cicatricial  conjunctivitis  are
distinctive features of ocular cGVHD [14]. Once dry eye
Figure 4. Immunohistochemical findings (MMP9 and MMP2). A-D: Consecutive sections from the case 1 sample. A, B: Intense MMP9
expression was seen in the stroma (A, B) and epithelium (B) near the perforation. C: MMP2 expression was not observed. E: Conjunctiva
sample from a cGVHD patient showing intense MMP9 expression (positive control). F: Control conjunctiva sample (negative control).
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603develops, even more severe dryness toward the center of the
cornea can easily occur. Dry eye related to cGVHD is often
associated  with  conjunctival  fibrosis,  trichiasis  due  to
cicatricial changes, and limbal stem cell deficiency, which
leads to corneal neovascularization [18,19].
In Sjögren's syndrome, corneal ulceration and perforation
associated with topical corticosteroid use have been reported
[20]. The authors of that study strongly recommend avoiding
topical  steroid  use,  to  prevent  corneal  perforation.  The
previous reports in Sjögren's syndrome suggest us to avoid
excessive  topical  corticosteroids  use,  particularly  because
their systemic use is necessary for HSCT recipients to prevent
or  treat  cGVHD.  It  is  also  necessary  to  avoid  ocular
complications  of  corticosteroid  use,  such  as  cataract,
glaucoma, and infection in HSCT recipients. This policy may
also reduce the risk of corneal perforation. It has been also
reported that the use of topical nonsteroidal anti-inflammatory
eyedrops  after  ocular  surgery  is  associated  with  corneal
melting [21,22]. Topical eyedrops might be a culprit for the
development of corneal perforation in cGVHD.
The  corneal  perforations  in  this  case  series  were  all
paracentral or central. This localization may be resembling
neurotrophic ulcer and limbal stem cell deficiency, which are
frequent features of chronic inflammation [23,24]. The idea
that inflammatory or immune responses could increase the
risk  of  corneal  perforation  in  cGVHD  is  consistent  with
reports of corneal perforation in autoimmune diseases like
rheumatoid arthritis and Sjögren’s syndrome, and in corneal
infections.  Interestingly,  these  conditions  also  result  in
paracentral perforations, as in our series [25-29].
In addition, sections through the corneal perforation site
of  our  cases  1  and  4  showed  an  increased  infiltration  of
CD68+ macrophages and immunostaining for MMP9. The
accumulation of CD68+ macrophages at the site of corneal
perforation reflects local immune responses, including the
inflammatory response. CD68+ macrophages might engulf
and destroy the recipient’s damaged corneal tissues, leading
to the release of large amounts of pro-inflammatory cytokines
and inducing the expression of MMPs (Figure 5), but it is not
clear whether the CD68+ macrophage infiltration is a primary
event, which may induce corneal perforation, or a response to
it. Further study is needed to clarify this issue.
MMPs  participate  in  extracellular  matrix  remodeling
during acute and chronic inflammation. They regulate the
inflammatory cascade by acting on inflammatory mediators
and their receptors [30]. Several studies suggest a relationship
between  MMP9  expression  and  dry  eye  or  other  ocular
diseases, including recurrent corneal melting in patients with
primary Sjögren’s syndrome [25] and melted corneal grafts
[31]. Overexpression of MMP2 in the cornea and the presence
of  MMP9  in  the  tear  film  have  been  found  in  cases  of
peripheral  ulcerative  keratitis  [32].  Thus,  MMP9  may  be
involved in the pathology that led to corneal perforation in our
series of patients. MMP9 can be expressed by macrophages,
the  corneal  epithelium,  extracellular  matrix,  and/or  in
response to cell-cell interactions; in contrast, only keratocytes
secrete MMP2 in the eye [24]. In any case, understanding the
mechanisms  resulting  in  dry  eye,  inflammatory  cell
infiltration  into  the  cornea,  and  the  pattern  of
MMP9 expression in the corneal microenvironment will help
to clarify some of the processes leading to corneal perforation
in cGVHD patients. The blockade of MMP9 expression and
inhibition  of  macrophage  infiltration  may  be  useful  for
preventing corneal perforation in these patients.
Furthermore, Suzuki et al. [10] reported that CD8+ T cells
infiltrating the perforated cornea play an important role in the
perforation, and strongly suggested that corneal perforation in
ocular  cGVHD  results  from  CD8+  T  cell-mediated
cytotoxicity  an  idea  that  is  compatible  with  cGVHD
pathology. These findings fit with cGVHD’s similarity to an
autoimmune  disease,  that  is,  as  a  disease  of  dysregulated
immunity  with  multiple  manifestations  [33].  Finally,
Figure 5. Hypothetical etiology of corneal perforation in cGVHD patients. CD68+ macrophages engulf and degrade the recipient’s degenerated
epithelium as a foreign body, leading to the secretion of a large amount of proinflammatory cytokines, and the subsequent expression of MMP9
on macrophages or the corneal stroma and epithelium.
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604mechanical stress caused by conjunctival fibrosis or the pre-
HSCT  preparative  regimen,  which  includes  total  body
irradiation and/or massive chemotherapy, could influence the
maintenance of the ocular surface.
Case control studies will be needed to identify clinical
factors that might elevate the risk of corneal perforation and
obtain more insight into the pathological processes that lead
to  corneal  perforation  in  patients  with  cGVHD  following
allogeneic HSCT. However, our study and previous reports
have several implications for clinical practice. Patients with
ocular  cGVHD  who  are  treated  with  topical  steroids  or
NSAIDS should be monitored closely due to the possible risk
of  corneal  perforation  and  the  potential  for  subsequent
blindness. Understanding how patients with ocular cGVHD
can avoid conditions that threaten their vision has become
increasingly important with the success of HSCT and the long-
term survival of greater numbers of patients. Our findings may
help reduce the risk of corneal perforation in some patients
with ocular cGVHD.
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